ReShape Lifesciences Expects 2024 Operating Expenses To Decrease By More Than 50% Compared to 2023; Reaffirming Commitment To Profitability
ReShape Lifesciences預計,與2023年相比,2024年的運營支出將減少50%以上;重申對盈利的承諾
ReShape Lifesciences Expects 2024 Operating Expenses To Decrease By More Than 50% Compared to 2023; Reaffirming Commitment To Profitability
ReShape Lifesciences預計,與2023年相比,2024年的運營支出將減少50%以上;重申對盈利的承諾
使用瀏覽器的分享功能,分享給你的好友吧